Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 46INDUSTRY 32OTHER_GOV 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 4Recurrence 2Vomiting 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hypersensitivity 1Disease Progression 1

Interventions

Drug Therapy 4pembrolizumab 3Thermography 2Surveys and Questionnaires 2Standard of Care 2Quality of Life 2Preoperative Exercise 2Nivolumab 2Moxibustion 2Hematologic Tests 2Cyclophosphamide 2Chemoradiotherapy 2vandetanib 1sinovac COVID-19 vaccine 1lenvatinib 1ibrutinib 1fludarabine 1encorafenib 1durvalumab 1binimetinib 1beta Carotene 1avelumab 1atezolizumab 1Zoledronic Acid 1Zinc 1Vitamin E 1Vascular Access Devices 1Validation Studies as Topic 1Urination 1Ultraviolet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Neoplasms × Dexamethasone × Clear all
NCT04430361 2020-06-12

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡